Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:brand
gptkb:drug |
| gptkbp:alternativeBrandName |
gptkb:Extavia
|
| gptkbp:approvalYear |
1993
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:L03AB08
|
| gptkbp:contraindication |
hypersensitivity to interferon beta-1b
|
| gptkbp:form |
lyophilized powder for injection
0.3 mg per vial |
| gptkbp:frequency |
every other day
|
| gptkbp:genericName |
gptkb:interferon_beta-1b
|
| https://www.w3.org/2000/01/rdf-schema#label |
Betaseron
|
| gptkbp:indication |
relapsing forms of multiple sclerosis
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Bayer
|
| gptkbp:marketedIn |
gptkb:Europe
gptkb:United_States |
| gptkbp:mechanismOfAction |
immunotherapy
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
gptkb:depression
injection site reaction flu-like symptoms liver enzyme elevation |
| gptkbp:usedFor |
multiple sclerosis
|
| gptkbp:bfsParent |
gptkb:Cetus_Corporation
|
| gptkbp:bfsLayer |
5
|